RISE Life Science: Commitment to the Highest Quality Cannabis Products for Sexual Health and Wellness


Robin Lefferts

May 24th, 2018

Exclusive, News, Top News


As the cannabis industry matures, both in North America and across the globe, regulations and consumer demands will require companies to produce consistent, high quality products that are safe and effective. Gone are the days of illicit weed grown with questionable practices, as the black market is being replaced by regulated operations offering a variety of cannabis products scientifically developed for use in distinct applications. With the wide variety of strains and chemical profiles now available to companies making legal cannabis products, a commitment to sourcing quality plants and developing scientifically researched products tailored for a range of needs is more important than ever.

RISE Life Science Corp. (CSE: RLSC) is a prime example of a company committed to quality from start to finish. RISE is creating a line of cannabis-derived sexual health and wellness products that it intends to market globally, starting in California. From sourcing the best cannabis strains, to rigorous research and development standards, to the commencement of a major cannabis/sexual health study, the company is committed to the highest standards throughout the entire life cycle of product development.

Quality Starts with the Plant

Working toward the highest level of quality, RISE plans to use the best plant sources for the consumer products it develops. As such, the company is exploring a comprehensive supply partnership with Jamaican premium strain producers who meet standards for CGMP (current good manufacturing processes) as set out by the FDA. These standards are designed to assure that quality is built into the design and manufacturing process at every step; facilities are in good condition; equipment is properly maintained and calibrated; employees are qualified and fully trained; and, processes are reliable and reproducible.

Jamaica is not only considered one of the best growing regions in the world, it is also viewed as one of the most experienced, producing cannabis for well over 400 years. With such a deeply established botanical relationship it is no surprise that Jamaican marijuana strains are widely recognized as some of the highest quality in the world.

RISE is targeting strains with the appropriate terpene and cannabinoid profiles to form the basis for its medical line of products to ensure that only the highest quality raw material is utilized in the formulation and development process.

Laboratory Science Important for RISE

RISE Life Science is partnered with experts in the manufacture of premium medical cannabis extract products for physician and patient use. They are leveraging deep experience with whole plant extracts utilizing proprietary extraction and compounding methods.

RISE is launching in California, but has its eyes on markets around the world. International certification is important for companies pursuing global market opportunities. With a patchwork of regulatory demands across markets, the company is seeking the highest-regarded quality control standards in another indication of RISE’s commitment to quality and global acceptance for its products.

“Validated science is at the core of our product development,” said Anton Mattadeen, CEO of RISE. “Our focus is on producing pharmaceutical grade product derived from highly-controlled processes that are continually supported by a feedback of observational data.”

The formulations of RISE products also draw heavily from botanical traditions. To this end, the company’s product formulation strategy relies on herbal specialists based out of Colorado. RISE’s lead herbalist brings 30 years of experience to the company’s product development.

Sexual Health Study Underpins Product Development

Future products will be developed with insights gained from a proprietary research study RISE will launch this fall. It will be the largest observational study of its kind, looking at the effect of cannabis health products on sexual health, behaviors, and performance.

The RISE Report on Cannabis and Sexual Health and Wellness intends to answer many questions that have gone unanswered, and unstudied, as a result of the long-term prohibition of cannabis and research related to the plant. Starting with about 200 beta participants, the study will expand to thousands of people and the data derived should be valuable in a number of ways.

“We are investing in this study because it is central to the ongoing development of consumer products that individuals and couples believe in and actually want to use,” continued Mattadeen. “The proprietary data generated by this study will not only add necessary information to the subject of sexual health, it will also inform RISE of the best possible product development decisions to meet the needs of our customers, provide us with a competitive advantage in the marketplace, and help us remain right in the middle of this important conversation with our expanding consumer community.”

For RISE, the most obvious benefit will lie in how the findings can inform and improve the company’s own product development. The company views this outcome as a competitive advantage in a market rife with un-researched products and wild claims of efficacy. The data would also add more generally to the growing library of science surrounding cannabis, potentially adding more credence to the idea of using the plant as a legitimate treatment and eliminating some of the social taboos around both marijuana and sex.

All told, RISE Life Science is demonstrating its commitment to quality ingredients, practices, and products based on the science of cannabis. With an initial product launch coming soon in California, keep an eye out for further developments in RISE’s quest to legitimize cannabis as a tool to improve lives of consumers and patients wherever the law allows.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading